Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01165996 · BASELINE

Baseline characteristics

Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome · Source last updated 2019-03-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      25
    units
    Participants
groups
  1. description
    INDUCTION PHASE: Patients receive decitabine subcutaneously (SQ) twice weekly for 4 weeks or thrice weekly until achieving bone marrow blasts \< 5%. MAINTENANCE PHASE: Patients then receive decitabine SQ twice weekly for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
    id
    BG000
    title
    Arm I: Decitabine 0.2mg/kg
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          1
      title
      40-49 years
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          1
      title
      50-59 years
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          8
      title
      60-69 years
    4. categories
      1. measurements
        1. group Id
          BG000
          value
          9
      title
      70-79 years
    5. categories
      1. measurements
        1. group Id
          BG000
          value
          6
      title
      80-89 years
    param Type
    NUMBER
    title
    Age, Customized
    unit Of Measure
    participants
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          11
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          14
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          25
      title
      United States
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      25
    units
    Participants
groups
  1. description
    INDUCTION PHASE: Patients receive decitabine subcutaneously (SQ) twice weekly for 4 weeks or thrice weekly until achieving bone marrow blasts \< 5%. MAINTENANCE PHASE: Patients then receive decitabine SQ twice weekly for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
    id
    BG000
    title
    Arm I: Decitabine 0.2mg/kg
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          1
      title
      40-49 years
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          1
      title
      50-59 years
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          8
      title
      60-69 years
    4. categories
      1. measurements
        1. group Id
          BG000
          value
          9
      title
      70-79 years
    5. categories
      1. measurements
        1. group Id
          BG000
          value
          6
      title
      80-89 years
    param Type
    NUMBER
    title
    Age, Customized
    unit Of Measure
    participants
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          11
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          14
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          25
      title
      United States
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice